ALKEM - Alkem Laboratories Limited Share Price

Management's outlook for FY '27 indicates a focus on driving growth and profitability through enhancing execution, improving portfolio mix, and expanding their differentiated pipeline. They are optimistic about maintaining momentum despite facing challenges such as increased logistics costs and pressure on APIs and packaging materials due to geopolitical dynamics. This could lead to near-term headwinds, but management is actively monitoring these trends and believes they are well-positioned to mitigate potential disruptions.

Key highlights include:

• EBITDA surpassed INR 3,000 crores in FY '26, a growth of 19.6% Y-o-Y, with an EBITDA margin of 20.4%.
• Total revenue from operations for FY '26 was INR 147,123 million, reflecting a Y-o-Y growth of 13.5%. India sales were INR 98,514 million (9.7% growth), while international sales amounted to INR 4,610 million (22.5% growth).
• R&D expenses for FY '26 were INR 6,173 million, accounting for 4.2% of total revenue.
• Management expects to maintain an EBITDA margin within a range of 20% to 21%, albeit contingent on geopolitical stabilization.

Further, they reported a successful launch of semaglutide, capturing an 11% market share shortly after launch, which they anticipate will contribute significantly to chronic therapy growth. Management has also detailed the planned tax rate decrease to around 27%-29% going forward, which is expected to enhance cash accumulation.

In summary, management remains committed to executing their long-term strategy while navigating external challenges to sustain their growth momentum in the upcoming financial year.

Q&A Section Summary from Alkem Laboratories Q4 FY2026 Earnings Call

1. Question: What type of strategic levers are you prioritizing in FY '26, '27 to expand Alkem's domestic formulation leadership?

Answer: We don't have new strategic levers for '26, '27. We will continue our existing strategy that has yielded positive results. For instance, the launch of GLP-1 semaglutide is performing well, enhancing growth in chronic therapies, which is a major focus. The domestic business is paramount, and we expect continued growth from our existing launches and strategic expansion in manpower to bolster chronic segment performance.

2. Question: What type of capital allocation and risk management framework have been applied in '26, '27 to balance dividend payouts with R&D funding?

Answer: We implement a forex policy where we hedge 80% of our exposure. We are cautious with raw material costs due to ongoing increases. For capital allocation, we prioritize integrating our Occlutech acquisition before further investments. Our dividend policy remains at 25-30% of PAT. As we shift to the new tax regime, we anticipate an increase in our cash accumulation, allowing for sustained dividends despite a rising tax rate in FY '27.

3. Question: Given that we have grown this year at close to about 10%, how should we think about growth going forward in the India business including trade generics?

Answer: We aim to maintain growth at 100-150 basis points above market growth. With semaglutide's launch, we expect this trajectory to continue. The trade generic segment had a tough year growing around 4.3% due to restructuring, but we focus on profitability rather than just top-line growth, so we expect an improved trajectory moving forward as we stabilize the business.

4. Question: How do you see the margin improvement guidance in light of current cost pressures?

Answer: The geopolitical landscape significantly affects margins. Originally, we anticipated 100 basis points of margin improvement annually, but due to current uncertainties in pricing and inflation, sustaining margins at FY '26 levels may be more realistic for now. We're taking measures to mitigate risks, aiming for clearer insights by H2 FY '27.

5. Question: Can you provide a regulatory launch timeline for the Denosumab portfolio and pricing pressure strategies?

Answer: We are currently seeking approval, with expectations for potential launches in Q1 FY '27. Pricing pressures are a concern across the industry. Our strategy involves partnership with European firms to manage pricing effectively, and we will pursue partnerships for market entry to mitigate competitive pricing.

6. Question: What growth estimates or internal budgets do you have for FY '27 across various business lines?

Answer: For FY '27, we anticipate domestic growth will remain 100-150 basis points ahead of market growth, likely translating to double-digit increases. The U.S. market is expected to achieve high single-digit growth, supplemented by potential currency gains and new product launches, while ROW markets may see high-teen growth.

7. Question: What is the expected timing for the Occlutech acquisition, and when will those contributions be reflected in Alkem's results?

Answer: The Occlutech acquisition is expected to finalize in 45-60 days. Once completed, we anticipate seeing contributions included in the results starting from Q2 FY '27.

These questions and their respective answers provide significant insight into Alkem Laboratories' strategic outlook, financial health, and operational plans moving forward.